436 related articles for article (PubMed ID: 7938926)
21. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults.
Hak E; Grobbee DE; Sanders EA; Verheij TJ; Bolkenbaas M; Huijts SM; Gruber WC; Tansey S; McDonough A; Thoma B; Patterson S; van Alphen AJ; Bonten MJ
Neth J Med; 2008 Oct; 66(9):378-83. PubMed ID: 18990781
[TBL] [Abstract][Full Text] [Related]
22. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults.
Metlay JP; Fishman NO; Joffe M; Edelstein PH
Vaccine; 2006 Jan; 24(4):468-75. PubMed ID: 16125826
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population.
Castañeda-Orjuela C; Alvis-Guzmán N; Paternina AJ; De la Hoz-Restrepo F
Vaccine; 2011 Oct; 29(44):7644-50. PubMed ID: 21854825
[TBL] [Abstract][Full Text] [Related]
24. Pneumococcal vaccination in older adults.
Marras TK
N Engl J Med; 2003 Aug; 349(7):712-4; author reply 712-4. PubMed ID: 12924340
[No Abstract] [Full Text] [Related]
25. [Antipneumococcal vaccine: up date and prospective].
Caramia G; Pastorelli G
Minerva Pediatr; 2005 Oct; 57(5):229-41. PubMed ID: 16205607
[TBL] [Abstract][Full Text] [Related]
26. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age > or = 65.
Whitney CG
Geriatrics; 2003 Oct; 58(10):20-2, 25. PubMed ID: 14569639
[TBL] [Abstract][Full Text] [Related]
27. Pneumococcal conjugate vaccine use in adults.
Isturiz RE; Schmoele-Thoma B; Scott DA; Jodar L; Webber C; Sings HL; Paradiso P
Expert Rev Vaccines; 2016; 15(3):279-93. PubMed ID: 26651847
[TBL] [Abstract][Full Text] [Related]
28. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia.
Fisman DN; Abrutyn E; Spaude KA; Kim A; Kirchner C; Daley J
Clin Infect Dis; 2006 Apr; 42(8):1093-101. PubMed ID: 16575726
[TBL] [Abstract][Full Text] [Related]
29. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia.
Musher DM; Rueda-Jaimes AM; Graviss EA; Rodriguez-Barradas MC
Clin Infect Dis; 2006 Oct; 43(8):1004-8. PubMed ID: 16983612
[TBL] [Abstract][Full Text] [Related]
30. Influenza and pneumococcal vaccination of the elderly: newer vaccines and prospects for clinical benefits at the margin.
Fedson DS
Prev Med; 1994 Sep; 23(5):751-5. PubMed ID: 7845953
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
32. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
[TBL] [Abstract][Full Text] [Related]
33. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
Silfverdal SA; Berg S; Hemlin C; Jokinen I
Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
[TBL] [Abstract][Full Text] [Related]
34. Pneumococcal vaccine development.
Poolman JT
Expert Rev Vaccines; 2004 Oct; 3(5):597-604. PubMed ID: 15485339
[TBL] [Abstract][Full Text] [Related]
35. Invasive pneumococcal disease in children aged <5 years admitted to 3 urban hospitals in Ibadan, Nigeria.
Falade AG; Lagunju IA; Bakare RA; Odekanmi AA; Adegbola RA
Clin Infect Dis; 2009 Mar; 48 Suppl 2():S190-6. PubMed ID: 19191615
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
[TBL] [Abstract][Full Text] [Related]
37. Pneumococcal vaccines: World Health Organization position paper.
Can Commun Dis Rep; 1999 Sep; 25(17):150-1. PubMed ID: 10513118
[TBL] [Abstract][Full Text] [Related]
38. [Cost-benefit analysis of vaccination against pneumococcal pneumonia].
Ament AJ; Sprenger M; Botman MJ; Sasburg RH; de Waard J
Ned Tijdschr Geneeskd; 1986 Mar; 130(9):407-10. PubMed ID: 3083271
[No Abstract] [Full Text] [Related]
39. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention.
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):189-209. PubMed ID: 19296419
[TBL] [Abstract][Full Text] [Related]
40. Pneumococcal polysaccharide vaccine may not prevent hospitalization for pneumonia in elderly individuals.
Skull SA; Andrews RM; Byrnes GB; Kelly HA; Nolan TM; Brown GV; Campbell DA
Clin Infect Dis; 2007 Feb; 44(4):617; author reply 617-8. PubMed ID: 17260423
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
